Truist Financial Sticks to Their Buy Rating for BioMarin Pharmaceutical (BMRN)
I'm PortAI, I can summarize articles.
Truist Financial analyst Joon Lee reiterated a Buy rating for BioMarin Pharmaceutical, setting a price target of $100. Lee, who covers the Healthcare sector, has an average return of 36% and a 60.75% success rate on recommended stocks. BioMarin also received a Buy rating from Dex Genotek, while H.C. Wainwright maintained a Hold rating.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments